Annexon (NASDAQ:ANNX - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.05), Zacks reports.
Annexon Stock Performance
NASDAQ ANNX traded down $0.08 during trading hours on Thursday, reaching $2.68. 792,661 shares of the company's stock were exchanged, compared to its average volume of 1,810,129. The company has a market capitalization of $285.67 million, a price-to-earnings ratio of -2.55 and a beta of 1.14. The company's 50-day moving average is $3.85 and its two-hundred day moving average is $5.38. Annexon has a one year low of $2.30 and a one year high of $8.40.
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on the company. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Annexon in a research report on Tuesday, December 17th. Needham & Company LLC restated a "buy" rating and set a $16.00 price objective on shares of Annexon in a report on Tuesday. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Annexon in a report on Friday, November 15th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $15.80.
Check Out Our Latest Report on ANNX
Annexon Company Profile
(
Get Free Report)
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
Featured Stories
Before you consider Annexon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.
While Annexon currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
